Tissue-specific augmentation of circadian PAI-1 expression in mice with streptozotocin-induced diabetes

Thrombosis Research

Volumn 114, Issue 2, 2004, Pages 129-135

  Oishi, Katsutaka ^a   Ohkura, Naoki ^b   Kasamatsu, Manami ^a   Fukushima, Nanae ^b   Shirai, Hidenori ^a,c   Matsuda, Juzo ^b   Horie, Shuichi ^b   Ishida, Norio ^a,c,d  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Circadian rhythm; Diabetes; Mice; Peripheral tissues; Plasminogen activator inhibitor 1; Streptozotocin

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; STREPTOZOCIN; TRANSCRIPTION FACTOR CLOCK;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; FIBRINOLYSIS; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEART; KIDNEY; LIVER; LUNG; MALE; MOUSE; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; STREPTOZOCIN DIABETES; TISSUE DISTRIBUTION; TISSUE SPECIFICITY;

ANIMALS; BIOLOGICAL MARKERS; CIRCADIAN RHYTHM; DIABETES MELLITUS, EXPERIMENTAL; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED ICR; ORGAN SPECIFICITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE DISTRIBUTION;

EID: 4043082666     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.05.011     Document Type: Article

References (32)

1. Yamamoto K., Saito H. A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders. Int. J. Hematol. 68:1998;371-385
2. Andreotti F., Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiol. Int. 8:1991;336-351
3. Maemura K., de la Monte S.M., Chin M.T., et al. CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression. J. Biol. Chem. 275:2000;36847-36851
4. Aronson D. Impaired modulation of circadian rhythms in patients with diabetes mellitus: a risk factor for cardiac thrombotic events? Chronobiol. Int. 18:2001;109-121
5. Haffner S.M. Insulin resistance, inflammation, and the prediabetic state. Am. J. Cardiol. 92:2003;18J-26J
6. Tsikouris J.P., Suarez J.A., Meyerrose G.E. Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents. J. Clin. Pharmacol. 42:2002;1187-1199
7. Yang H., Wright J.R. Jr. Human beta cells are exceedingly resistant to streptozotocin in vivo. Endocrinology. 143:2002;2491-2495
8. Oishi K., Kasamatsu M., Ishida N. Gene- and tissue-specific alterations of circadian clock gene expression in streptozotocin-induced diabetic mice under restricted feeding. Biochem. Biophys. Res. Commun. 317:2004;330-334
9. Gruden G., Cavallo-Perin P., Bazzan M., et al. PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria. Diabetes. 43:1994;426-429
10. Garcia Frade L.J., de la Calle H., Torrado M.C., et al. Hypofibrinolysis associated with vasculopathy in non insulin dependent diabetes mellitus. Thromb. Res. 59:1990;51-59
11. Carmassi F., Morale M., Puccetti R., et al. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb. Res. 67:1992;643-654
12. Aronson D., Weinrauch L.A., D'Elia J.A., et al. Circadian patterns of heart rate variability, fibrinolytic activity, and hemostatic factors in type I diabetes mellitus with cardiac autonomic neuropathy. Am. J. Cardiol. 84:1999;449-453
13. Auwerx J., Bouillon R., Collen D., Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis. 8:1988;68-72
14. Skrha J., Hodinar A., Kvasnicka J., Hilgertova J. Relationship of oxidative stress and fibrinolysis in diabetes mellitus. Diabet. Med. 13:1996;800-805
15. Hernandez C., Chacon P., Garcia-Pascual L., et al. Relationship between lipoprotein(a) phenotypes and plasminogen activator inhibitor type 1 in diabetic patients. Thromb. Res. 99:2000;119-127
16. Vague P., Juhan-Vague I. Fibrinogen, fibrinolysis and diabetes mellitus: a comment. Diabetologia. 40:1997;738-740
17. Schoenhard J.A., Smith L.H., Painter C.A., et al. Regulation of the PAI-1 promoter by circadian clock components: differential activation by BMAL1 and BMAL2. J. Mol. Cell. Cardiol. 35:2003;473-481
18. Oishi K., Miyazaki K., Kadota K., et al. Genome-wide expression analysis of mouse liver reveals CLOCK-regulated circadian output genes. J. Biol. Chem. 278:2003;41519-41527
19. Dennler S., Itoh S., Vivien D., et al. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 17:1998;3091-3100
20. Wilson H.M., Reid F.J., Brown P.A., et al. Effect of transforming growth factor-beta 1 on plasminogen activators and plasminogen activator inhibitor-1 in renal glomerular cells. Exp. Nephrol. 1:1993;343-350
21. Suzuki M., Akimoto K., Hattori Y. Glucose upregulates plasminogen activator inhibitor-1 gene expression in vascular smooth muscle cells. Life Sci. 72:2002;59-66
22. Kietzmann T., Samoylenko A., Roth U., Jungermann K. Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes. Blood. 101:2003;907-914
23. Hagiwara H., Kaizu K., Uriu K., et al. Expression of type-1 plasminogen activator inhibitor in the kidney of diabetic rat models. Thromb. Res. 111:2003;301-309
24. Gabriely I., Yang X.M., Cases J.A., et al. Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway. Atherosclerosis. 160:2002;115-122
25. Park I.S., Kiyomoto H., Abboud S.L., Abboud H.E. Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes. Diabetes. 46:1997;473-480
26. Shanmugam N., Reddy M.A., Guha M., Natarajan R. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes. 52:2003;1256-1264
27. Rerolle J.P., Hertig A., Nguyen G., et al. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int. 58:2000;1841-1850
28. Andreasen P.A., Georg B., Lund L.R., et al. Plasminogen activator inhibitors: hormonally regulated serpins. Mol. Cell. Endocrinol. 68:1990;1-19
29. Mayer M. Biochemical and biological aspects of the plasminogen activation system. Clin. Biochem. 23:1990;197-211
30. Bruzdzinski C.J., Johnson M.R., Goble C.A., et al. Mechanism of glucocorticoid induction of the rat plasminogen activator inhibitor-1 gene in HTC rat hepatoma cells: identification of cis-acting regulatory elements. Mol. Endocrinol. 7:1993;1169-1177
31. Sawdey M.S., Loskutoff D.J. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J. Clin. Invest. 88:1991;1346-1353
32. Vaughan D.E., Declerck P.J., Van Houtte E., et al. Studies of recombinant plasminogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivo. Circ. Res. 67:1990;1281-1286